Key points
- Strong balance sheet with A$19.7 million in cash and no debt
- US commercial pathway established for ROXUS
- SPONTAN Phase II advances FDA development pathway
- Over 1,000 SPONTAN prescriptions issued in Australia
- OROFLOW receives ethics approval for first clinical study
Full summary
LTR Pharma Limited (ASX:LTP) reported its full-year results for FY26, showcasing a strong balance sheet with A$19.7 million in cash and no debt. The company advanced its SPONTAN Phase II programme, showing promising pharmacokinetic results and no drug accumulation. SPONTAN's real-world use in Australia expanded, with over 1,000 prescriptions issued. LTR Pharma also established a commercial pathway for ROXUS in the US, completing key agreements. Additionally, OROFLOW received ethics approval for its first clinical study, extending LTR Pharma's intranasal platform beyond erectile dysfunction.
Outlook
LTR Pharma is focused on executing the US commercial launch of ROXUS, completing the SPONTAN Phase II analysis, and progressing SPONTAN towards Phase III.